Aphthous Stomatitis Following Ageusia in SARS-CoV-2 Reinfection: A Case Report

Introduction

Ageusia is one of the probable symptoms of coronavirus disease 2019 (COVID-19).[1] Complaints of the oral cavity of COVID-19 are still unclear as a manifestation or complication. The authors reported a case of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified as a patient’s oral complaint.

Publication History

Article published online:
27 September 2021

• References

• 1 World Health Organization. WHO COVID-19 : case definitions updated in public health surveillance for COVID-19. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020. Accessed 2020
• 2 Riad A, Klugar M, Krsek M.. COVID-19-related oral manifestations: early disease features?. Oral Dis 2020; Doi:
• 3 Cirillo N. COVID-19 outbreak: succinct advice for dentists and oral healthcare professionals. Clin Oral Investig 2020; 24 (07) 2529-2535
• 4 Mujayanto R, Indraswary R. Differential diagnosis of COVID-19 enanthema. Eur J Dent 2020; 14 (Suppl. 01) S179-S181 Doi:
• 5 Falahchai M, Babaee Hemmati Y, Hasanzade M. Dental care management during the COVID-19 outbreak. Spec Care Dentist 2020; 40 (06) 539-548
• 6 Santosh ABR, Muddana K. Viral infections of oral cavity. J Family Med Prim Care 2020; 9 (01) 36-42
• 7 Clarkson E, Mashkoor F, Abdulateef S. Oral viral infections: diagnosis and management. Dent Clin North Am 2017; 61 (02) 351-363
• 8 Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol 2000; 18 (05) 525-532
• 9 Rathee M, Jain P. Ageusia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Published 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK549775/. Accessed February 9, 2021
• 10 Nuno-Gonzalez A, Martin-Carrillo P, Magaletsky K. et al Prevalence of mucocutaneous manifestations in 666 patients with COVID-19 in a field hospital in Spain: oral and palmoplantar findings. Br J Dermatol 2021; 184 (01) 184-185
• 11 Galván Casas C, Català A, Carretero Hernández G. et al Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183 (01) 71-77
• 12 Beran J, Špajdel M, Katzerová V. et al Inosine pranobex significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic. Pathogens 2020; 9 (12) E1055
• 13 Srinivasan S, Torres AG, Ribas de Pouplana L. Inosine in biology and disease. Genes (Basel) 2021; 12 (04) 600
• 14 Tobaiqy M, Qashqary M, Al-Dahery S. et al Therapeutic management of patients with COVID-19: a systematic review. Infect Prev Pract 2020; 2 (03) 100061
• 15 Tan Q, Duan L, Ma Y. et al Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem 2020; 104: 104257
• 16 Holford P, Carr AC, Jovic TH. et al Vitamin C-an adjunctive therapy for respiratory infection, sepsis and COVID-19. Nutrients 2020; 12 (12) E3760
• 17 Propper RE. Smell/taste alteration in COVID-19 may reflect zinc deficiency. J Clin Biochem Nutr 2021; 68 (01) 3
• 18 Joachimiak MP. Zinc against COVID-19? Symptom surveillance and deficiency risk groups. PLoS Negl Trop Dis 2021; 15 (01) e0008895
• 19 Shakoor H, Feehan J, Mikkelsen K. et al Be well: A potential role for vitamin B in COVID-19. Maturitas 2021; 144: 108-111
• 20 MIMS. Becom-Zet. Available at: https://www.mims.com/indonesia/drug/info/becom-zet. Accessed April 1, 2021